Pathology and bio markers of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 3331, 1999, Pages 7-14

  Sakr, W A ^a   Brawer, M K ^a   Moul, J W ^a   Donohue, R ^a   Schulman, C G ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Molecular markers; Pathology; Prostate cancer; Prostatic intraepithelial neoplasia

Indexed keywords

EID: 27844596966     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500277     Document Type: Article

References (64)

1. Merrill RM, Potosky AL, Feuer EJ. Changing trends in U.S. prostate cancer incidence rates. J Natl Cancer Inst 1996; 88: 1683-1705.
2. Demeres RY. Prostate cancer trends in southeast Michigan. In Vivo 1994; 8: 429-431.
3. Wingo PA, Landis S, Ries LAG. An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin 1997; 47: 239-242.
4. Andrews GS. Latent carcinoma of the prostate. J Clin Path 1949; 2: 197-211.
5. Sakr WA, Haas GP, Cassin BJ, Pontes JE, Crissman JD. Frequency of prostatic intraepithelial neoplasia and invasive carcinoma in young males. J Urol 1993; 150: 379-385.
6. Breslow N et al. Latent carcinoma of the prostate at autopsy seven areas. Int J Cancer 1977; 20: 680-688
7. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986; 17: 64-71.
8. Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987; 59: 788-794.
9. Drago JR, Mostofi, FK, Lee F. Introductory remarks and workshop summary. Urology 1992; 39 (Suppl): 2-8.
10. Epstein JI et al. Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 1995; 19: 873-886.
11. Bostwick DG et al. Architectural pattterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol 1993; 24: 298-310.
12. Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE. The relationship between prostatic intraepithelial neoplasia and prostate cancer: Critical issues. J Urol 1997; 158: 12-22.
13. Sakr WA et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994; 54: 3273-3277.
14. Sakr WA et al. Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract 1995; 191: 838-841.
15. Langer JE et al. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol 1996; 155: 228-231.
16. Grignon DJ, Sakr WA. Atypical adenomatous hyperplasia of the prostate: A critical review. Eur Urol 1996; 30: 206-211.
17. Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: Clinical significance in 33 cases. Am J Surg Pathol 1997; 21: 1489-1495.
18. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 1995; 26: 223-229.
19. Kelemen PR, Buschmann RJ, Weisz-Carrington P. Nucleolar prominence as a diagnostic variable in prostatic carcinoma. Cancer 1990; 65: 1017-1020.
20. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-3593
21. AJCC Cancer Staging Manual. Philadelphia, PA: Lipincott-Raven, 1997; pp 219-224.
22. Grignon DJ, Sakr WA. Pathologic staging of prostate carcinoma: What are the issues? Cancer 1996; 15: 337-340.
23. Bostwick DG. Staging prostate cancer - 1997: Current methods and limitations. Eur Urol 1997; 32 (Suppl 3): 2-1.
24. Sakr WA et al. Staging and reporting of prostate cancer. Sampling the radical prostatectomy specimen. Cancer 1996; 78: 366-368.
25. Smith JA Jr. Stage T1c prostate cancer: Perspectives on clinical management. Semin Urol Oncol 1995; 13: 238-244.
26. Zietman AL et al. Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994; 43: 828-833.
27. Murphy GP, Whitmore WF Jr. A report of the workshop on the current status of the histologic grading of prostate cancer. Cancer 1979; 44: 1490.
28. Bain GO, Koch M, Hanson J. Feasibility of grading prostatic carcinomas. Arch Pathol Lab Med 1982; 106: 265.
29. Bostwick DG. Grading prostate cancer. Am J Clin Pathol 1994; 102 (Suppl): 538-556.
30. Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 1994; 43: 60-67.
31. Paulson DF, Walther PJ. Is grade or stage of primary importance in determining the outcome after radical prostatectomy for disease clinically confined to the prostate? Br J Urol 1989; 63: 301-305.
32. Brawer MK et al. Predictors of pathologic stage in prostatic carcinoma the role of neovascularity. Cancer 1994; 73: 678.
33. 32a Silberman F et al. The significance of atypical vessels and neovascularization in cervical neoplasia. Am J Obstet Gynocol 1981; 139: 154-159.
34. 32b Hall MC et al. Significance of tumor angiogenesis in chemically localized prostate carcinoma treated with external beam radiotherapy. Urology 1994; 44: 869-875.
35. Bostwick DG et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996; 48: 47-57.
36. Gettman MT et al. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology 1998; 51: 79-85.
37. Lissbrant IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997; 33: 38-45.
38. Rogatsch H et al. Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? J Pathol 1997; 182: 205-210.
39. Weingartner K, Kohler HH, Bittinger A Barth PJ. Assessment of the vascularization in prostatic carcinoma: a morphometric investigation. Hum Pathol 1996; 27: 1306-1310.
40. Krongrad A, Lai H, Li. S. Survival after radical prostatectomy. JAMA 1997; 278: 44A6.
41. Partin AW, Oesterling JE. The clinical usefulness of prostatic-specific antigen: update. J Urol 1994; 152: 1358-1368.
42. Bauer JJ et al. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Can Res 1995; ??: 1295-1300.
43. Chiusa L et al High and low risk prostate carcinoma determined by histologic grade and proliferative activity. Cancer 1997; 79: 1956-1963.
44. Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PC-NA) immunohistochemistly as a prognostic factor in prostatic carcinoma. J Pathol 1992; 168: 7-13.
45. Drachenberg CB, Loffe OB, Papadimitriou JC. Progressive increase of apoptosis in prostatic intraepithelial neoplasia and carcinoma: Comparison between in situ end-labeling of fragmented DNA and detection by routine hematoxylin-eosin staining. Arch Pathol Lab Med 1997; 121: 54-58.
46. Stapleton AM et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 1998; 82: 168-175.
47. Brothman AR. Cytogenetic studies in prostate cancer: are we making progress? Cancer Genet Cytogenet 1997; 95: 116-121.
48. Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol 1997; 10: 1113-1119.
49. Emmert-Buck MR et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995; 55: 2959-2962.
50. Bauer JJ et al. Elevatedlevels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol 1996; 156: 1511-1516.
51. Bettencourt MC et al. Ki-67 expression is an independent prognostic marker of recurrence in patients with organ confined prostate cancer after radical prostatectomy. J Urol 1996; 156: 1064-1068.
52. Bauer JJ et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 1997; 157 (Suppl): 298. Abstract.
53. Stackliouse GB et al. Immonohistochemical staining (IHC) for p53 and bcl-2 in needle biopsies of the prostate does not appear to predict clinical recurrence rate after radical prostatectomy. Proc Am Assoc Ca Res 1997; 38: 256.
54. Danziger M et al. Predictive accuracy of transrectal ultrasound-guided prostate biopsy: correlations to matched prostatectomy specimens. Urology 1997; 49: 863-867.
55. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997; 21: 566-576.
56. Fernandes ET, Sundaram CP, Long R, Soltani M, Ercole CJ. Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? Br J Urol 1997; 79: 615-617.
57. Fujinami K et al. Comparisons of histological grading between biopsy and radical prostatectomy specimens in prostatic adenocarcinoma. Nippon Hinyokika Gakkai Zasshi 1995; 86: 1460-1465.
58. Bostwick DG. Gleason grading of prostatic needle biopsies: Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994; 18: 796-803.
59. Catalona WJ, Stein AJ, Fair WR. Grading errors in prostatic needle biopsies: relation to the accuracy of tumor grade in predicting pelvic lymph node metastases. J Urol 1982; 127: 919-922.
60. Garnett JE, Oyasu R, Grayhack JT. The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification of radical prostatectomy specimens. J Urol 1983; 131: 690-693.
61. Mills SE, Fowler JE. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer 1986; 57: 346-349.
62. Lin DW et al. Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma. J Urol 1998; 160: 77-81.
63. Djavan B et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998; 160: 411-418.
64. Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 1997; 157: 1315-1321.